Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Genetic influence on the associations between IGF-I and glucose metabolism in a cohort of elderly twins

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Leo Niskanen
  • Lawrence A Leiter
  • Edward Franek
  • Jianping Weng
  • Taner Damci
  • Manuel Muñoz-Torres
  • Jean-Paul Donnet
  • Lars Endahl
  • Trine Vang Skjøth
  • Allan Vaag
Vis graf over relationer
Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30).
OriginalsprogEngelsk
TidsskriftEuropean Journal of Endocrinology
Vol/bind167
Udgave nummer2
Sider (fra-til)287-94
Antal sider8
ISSN0804-4643
DOI
StatusUdgivet - 2012

ID: 36878777